Significant Improvements Observed With Dupilumab in Prurigo Nodularis Trial
The phase 3 PRIME study evaluated dupilumab in 151 adults with inadequately controlled prurigo nodularis.
Pruritus And Dry Skin
New Drugs Approved in 2021
Visit our New Drug Products page to stay up-to-date on the latest drug approvals.
Dupilumab Reduced Itch, Skin Lesions in Patients With Prurigo Nodularis
The randomized, double-blind, placebo-controlled, parallel-group PRIME2 study included 160 patients with prurigo nodularis.
Korsuva Approved for Chronic Kidney Disease-Associated Pruritus
The approval was based on data from the pivotal phase 3 KALM-1 and KALM-2 trials, as well as data from an additional 32 clinical studies.
MPR Weekly Dose Podcast Episode 87
This week we have news of the FDA requesting a change to statin prescribing labels, a new vaccine for streptococcus pneumoniae, a new plaque psoriasis cream, a stem cell therapy gets fast tracked as a possible Parkinson disease treatment, and there’s a new treatment approved for Progressive Familial Intrahepatic Cholestasis.
Bylvay Approved for Progressive Familial Intrahepatic Cholestasis
Bylvay is an oral reversible inhibitor of the ileal bile acid transporter.
Sarna Eczema Relief Whipped Foam Now Available
The whipped foam formulation allows for rapid absorption to provide fast relief.
Rapid Relief Restoring Cream Added to AmLactin Product Line
AmLactin® Rapid Relief Restoring Cream is supplied in 12-ounce (340g) jars and costs $24.99.
FDA to Review Difelikefalin for Chronic Kidney Disease-Associated Pruritus
The NDA submission is supported by data from the pivotal phase 3 KALM-1 and KALM-2 trials.
FDA to Review Odevixibat for Progressive Familial Intrahepatic Cholestasis
Odevixibat is a potent, once-daily, non-systemic ileal bile acid transport inhibitor.
